Altis Biosystems has created a next-generation in vitro platform that reduces the time and cost of developing safer, more effective drugs.
By replicating native human biology, the stem cell platform produces more accurate and reproducible data for better clinical trial performance and reduces the need for animal testing.
The RepliGut® Platform
RepliGut® is a unique, stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.
With a scalable platform, actionable data, high throughput screening to test thousands of compounds, and an unrivaled biobank, RepliGut® is the future of in vitro testing during drug development.
The RepliGut® is a reproducible and scalable platform that is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.
NEWS AND ARTICLES
February 16, 2021
Recapitulating the Multifaceted Inflammatory Environment of the Intestine In Vitro
Current preclinical testing using assays based on cancer cells and animal models often results in high failure rates for drug candidates in the clinic. Microphysiological systems like Altis’s RepliGut™ human intestinal tissue model more accurately reflect human physiological environments, enabling more efficient and cost-effective drug discovery and development.Read More
December 23, 2020
How Does Altis Biosystems Envision the Future of the Pharma/Biopharma Industry?
There is a growing need to address the high failure rate of drug candidates as they progress through clinical trials. Altis Biosystems aims to bring its technological advances to the forefront, enabling the drug development process to more effectively translate results from preclinical experiments to late-stage clinical trials.Read More
Have a question? Want to stay informed about Altis, RepliGut, and more platforms currently under development? Send us a message!